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Abstract
Purpose of Review We review recent developments on risk factors in schizophrenia.
Recent Findings The way we think about schizophrenia today is profoundly different from the way this illness was seen in the
twentieth century. We now know that the etiology of schizophrenia is multifactorial and reflects an interaction between genetic
vulnerability and environmental contributors. Environmental risk factors such as pregnancy and birth complications, childhood
trauma, migration, social isolation, urbanicity, and substance abuse, alone and in combination, acting at a number of levels over
time, influence the individual’s likelihood to develop the disorder.
Summary Environmental risk factors together with the identification of a polygenic risk score for schizophrenia, research on
gene–environment interaction and environment–environment interaction have hugely increased our knowledge of the disorder.
Keywords Schizophrenia . Psychosis . Risk factors . Environment . Gene–environment interaction . Childhood trauma .
Cannabis
Introduction
Schizophrenia has a well-established genetic component,
which can now be estimated using the polygenic risk score
for schizophrenia [1, 2••]. In the ground-breaking meta-anal-
ysis of genome-wide association study (GWAS) of schizo-
phrenia, 108 schizophrenia-associated loci were identified
[2••]. The loci implicated include genes involved in dopamine
synthesis, calcium channel regulation, immunity, and gluta-
mate neuroreceptors. However, this and subsequent GWAS
studies explain only a minority of the variance in the liability
for schizophrenia in the general population. This reflects the
fact that a significant proportion of the liability may be due to
gene–environment interactions [3] or to epigenetic
mechanisms reflecting the effect of environmental factors.
Indeed, growing evidence shows that non-genetic risk factors
not only contribute to the illness but also suggest ways in
which we may find potential subgroups of subjects at higher
risk and therefore influence clinical management.
Pregnancy and Birth Complications
Obstetric complications are well-documented as a risk factor
for schizophrenia [4•,5–7]; increased susceptibility has been
associated with emergency cesarean section, bleeding during
pregnancy, preeclampsia [6], and low birth weight [8–10]. Use
of forceps and low birth weight predict earlier age of onset of
psychosis [11].
Some epidemiologic studies have also suggested that ex-
posure to viruses and other infectious agents such as influenza,
toxoplasmosis, and herpes simplex virus type 2, contracted
during pregnancy [12, 13] and around the time of conception
[14], are associated with a later risk of psychotic disorders.
However, these results have not always been replicated. For
example, a recent meta-analysis by Selten et al. has shown
insufficient evidence to prove an association between
second-trimester influenza exposure and psychotic outcome
in the offspring [15••].
Four main pathogenic mechanisms have been suggested as
involved: fetal malnutrition, prematurity, hypoxic-ischemic
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events, and maternal infections during pregnancy or delivery
[4•, 16–20]. Moreover, elevated markers of inflammation, in-
cluding maternal C-reactive protein [21] and interleukin-8
[22] have been found in mothers of patients with schizophre-
nia. Late winter or spring birth has often been reported as risk
factor for schizophrenia [8, 23–25]. However, it has a very
small effect [26]; whether it is secondary to maternal infection
or nutritional deficiency remains unclear.
Advanced Parental Age
Increased paternal age, from age higher than 34 and upwards
[27, 28], has been associated with schizophrenia [29–31]. An
attractive theory suggests that age-associated increase in spo-
radic de novo mutations in male germ cells may play a role
[32–34]. However, this was discounted by a study from
Denmark that suggests that late marriage and reproduction
may be due to personality attributes of fathers [35].
A less consistent pattern of findings has emerged regarding
maternal age at birth and risk of schizophrenia in offspring. In
one study, age younger than 19 and age older than 40 years
[36] appeared to increase the risk. However, in another cohort
study, the risk appeared decreased in offspring of mothers
older than 30 years [37]. Lopez-Castroman et al. (2010) found
a significant linear association increase only with advancing
maternal age [38].
Trauma and Social Adversities
Trauma and social adversities in different forms, either during
childhood or adulthood, have been extensively investigated as
potential risk factors for schizophrenia. Varese and colleagues,
in a meta-analysis of case-control, prospective, and cross-
sectional cohort studies, reported strong evidence that child-
hood adversity (defined as sexual abuse, physical abuse,
emotional/psychological abuse, neglect, parental death, and
bullying) was associated with increased risk for psychosis in
adulthood (overall OR = 2.78) [39•]. There is an association
between permanent separation from, or death of, one or both
parents and psychosis [40–43], victimization and bullying and
psychosis [44–46]. A robust link between childhood trauma
and schizophrenic symptoms has been found [47–49] with
childhood trauma being associated with the most severe forms
of positive symptomatology in adulthood, particularly hallu-
cinations [49–51], and affective symptoms [52]. Life events
more proximal to the onset of illness, defined as situations that
bring about positive or negative changes in personal circum-
stances and/or involve an element of threat, have been inves-
tigated [53–55]. The most recent review and meta-analysis of
the relationship between life events and psychosis has sug-
gested around a threefold increased odds of life events in the
period prior to psychosis onset, with the time period under
consideration ranging between 3 months and 3.6 years [55].
Social Class and Isolation
Some reports link social inequality at birth with schizophrenia.
Socioeconomic status (usually measured by paternal occupa-
tion) has been reported to be associated with an increased risk
of psychosis [56–60]. However, while some findings are pos-
itive, there are a number of conflicting studies showing no
association between psychosis and low social class at birth
[41] or even a link with high social class [61, 62].
Markers of isolation/disadvantage, alone and cumulative, are
also associatedwith psychosis [42, 43, 63]. First-episode psycho-
sis patients are more likely to live alone; be single or unem-
ployed; live in a rented accommodation, in overcrowded condi-
tions; and receive an income below official poverty, not only at
first contact with psychiatric services but up to 5 years prior to the
onset of psychosis, with around a twofold increased odds [43].
The World Health Organization (WHO) studies have reported
that despite the better access to biomedical treatment, higher rates
of chronic disability and dependency in schizophrenia occur in
high- than low-income countries and suggest that something
essential to recovery is missing in the social fabric [64].
Migration
Meta-analytic reviews show thatmigrant groups are at increased
risk of schizophrenia and other psychotic disorders [65, 66•].
These findings have been consistently replicated in a number of
high-income countries: the UK [67], the Netherlands [68],
Germany [69], Denmark [70], France [71], Italy [72], and to a
lesser extent Canada [73] with some evidence that the risk of
schizophrenia and other non-affective psychotic disorders is es-
pecially high among refugees compared with non-refugee mi-
grants [74]. Interestingly, the risk appears to persist into the
second and third generations [66•, 75].
The level of risk appears to vary by country of origin. A
recent meta-analysis of schizophrenia incidence in the UK re-
ported almost a five times greater risk of schizophrenia among
people of black Caribbean origin compared with reference UK
population (usually white) [76]. Numerous hypotheses have
been tested. Higher incidence rates in the country of origin,
selective migration, or misdiagnosis of mood disorders do not
seem to explain the phenomena [77–81]. However, social ad-
versity exposures at all stages of the migration process (before,
during, and after) [82], low ethnic density [83], social isolation
[84], discrimination [68], and lack of access to private accom-
modation and economic opportunities [85] have all been sug-
gested as contributing, so has vitamin D deficiency [86, 87] but
as yet little direct evidence for the latter has been found.
Urbanicity
Growing up and/or living in an urban environment has fre-
quently been associated with an increased risk of
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schizophrenia or psychosis in general [88–91]. A meta-analy-
sis, including a total of 47,087 cases with psychosis, shows a
pooledOR for psychosis in urban environment comparedwith
the rural environment of 2.39 (95% CI 1.62–3.51) [92•].
Changing residence in childhood from rural to urban environ-
ment doubles the risk of developing schizophrenia [93, 94],
and the more years a child spends in an urban area, the greater
the risk becomes [95].Many explanations have been proposed
such as greater exposure to prenatal influenza [96], maternal
obstetrical complications [97, 98], toxoplasma gondii infec-
tion [99], cannabis use [100], social deprivation, income in-
equality, and social fragmentation [101, 102] but none of them
has been verified. Furthermore, while the largest multicentric
study of first-episode psychosis patients to date (EU-GEI
study) confirmed higher incidence in Northern European cit-
ies including London, Amsterdam, and Paris, the increased
density effect is not so clear in Southern European settings
[103•].
Interestingly, a recent study conducted in Denmark, has
pointed out for the first time the protective role of living in,
or near to, a green area, showing a dose-response association
between the magnitude of greenspace during childhood and
the risk of later development of schizophrenia [104•].
Cannabis and Other Substance Use
Substance use is highly prevalent in psychotic patients
[105–107]. There is good evidence that psychostimulants
(such as amphetamines and cocaine) can induce psychosis
[108]. There also have been a few suggestions that alcohol
misuse and psychosis might be associated [109, 110], and
recently, a meta-analysis raised the question of whether tobac-
co use could be a risk factor for psychosis [111]. However,
much greater evidence points to an important aetiological role
for cannabis use. Prospective epidemiological studies consis-
tently report an association between cannabis use and schizo-
phrenia [112–114] with an estimated two- to threefold in-
creased risk [114, 115]. A dose–response relationship between
extent of use and risk of psychosis has been shown in a meta-
analysis [116]. The association is stronger in those individuals
who used cannabis earlier [113], and who used high potency
tetrahydrocannabinol (THC) cannabis or/and more frequently
[112, 117, 118]. Indeed, the EU-GEI study has found that if
high-potency cannabis was no longer available, around
12% of first-episode psychosis cases across 11 Europe-
wide sites could be prevented, rising to 30% in London
and 50% in Amsterdam [119•]. The age at which cannabis
use begins appears to correlate with the age at onset of
psychosis [118, 120, 121] while persistent cannabis use
after a first episode is associated with poorer prognosis
[122, 123], higher relapse rates, longer hospitalizations,
and severe positive symptoms [124].
Cognitive Impairments and Brain Structural
Abnormalities
Although schizophrenia usually manifests in adolescence and
early adult life, numerous reports suggest that many patients with
schizophrenia have a history of delayed developmental mile-
stones in the first year of life [125], lower IQ in childhood
[126–128], hearing impairment [129], emotional problems, and
interpersonal difficulties early in life [130, 131]. Those people
who develop psychosis following heavy cannabis use show less
evidence of such neurodevelopmental deviance. In particular,
they have higher premorbid IQ and better social functioning in
childhood than psychotic patientswho do not use cannabis [132].
Perhaps being smarter and more sociable enables them to find
cannabis dealers and obtain the money for the drug!
Gene–Environment Interaction
It is becoming increasingly clear that none of the risk factors
discussed above, by itself, is either necessary or sufficient for
the development of schizophrenia. Most of show a modest
effect (twofold increase in risk) and none seem specific for
schizophrenia. Different factors operating at various levels
contribute to onset and progression of the disorder. The devel-
opmental cascade towards schizophrenia [133] should now
include gene–environment interaction (GXE), and
environment–environment interaction (EXE) (Fig. 1).
Interest has turned to the possibility of gene × environmental
interactions. Preliminary reports suggested interactions between
functional polymorphisms in the catechol-O-methyltransferase
gene [134], or theDRD2 genotype (OMIM 126450) [135], and
the AKT1 genotype (C/C rs2494732) [136, 137] and cannabis
use, on risk of psychosis. However, all of these studies are
relatively small and in need of replication. A few preliminary
studies have examined interactions between the polygenic risk
score for schizophrenia (e.g., Trotta et al. [138]; Ursini et al.
[139]) but there are not sufficient studies yet to evaluate this
adequately. The largest and most recently published study to
date, analyzing the associations of polygenic risk score for
schizophrenia and environmental exposures in 1699 patients
and 1542 unrelated controls, shows an additive interaction be-
tween polygenic risk score and lifetime regular cannabis use and
exposure to early life adversities (sexual abuse, emotional
abuse, emotional neglect, and bullying), but not with the pres-
ence of other exposures such as hearing impairment, winter
birth, physical abuse, or physical neglect [140••] confirming
the need for future confirmatory studies.
Cumulative Effect of Environmental Risk Factors
A few studies have now started examining the additive effect
of multiple environmental factors on risk of psychosis as ag-
gregate index of total number of risk factors or weighted sum.
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Cougnard et al. reported an additive interaction between ex-
posure to three risk factors—cannabis use, childhood trauma,
and urbanicity—and baseline psychotic experiences in
predicting persistent psychotic symptoms three years later in
the general population [141]. Stepniak et al. found that indi-
viduals who had been exposed to 4 or more environmental
risk factors had a significantly lower age of onset than those
exposed to 3 factors [142]. As a predictor tool, Padmanabhan
et al., in a pilot study, explored the association of cumulative
environmental risk (including nine risk factors) with conver-
sion to psychosis in a family high-risk population [143].
Neurochemical Mechanisms
Different systems: dopaminergic (DA), glutamatergic, neuroin-
flammation/immune, andmore recently endocannabinoid (eCB),
have all been investigated to understand the exact mechanism(s)
by which some non-genetic risk factors can affect brain function.
The predominant biological theory of schizophrenia highlights
the role of the excess presynaptic synthesis of DA in the striatum
in the onset of positive symptoms [144•, 145]. Consistent with
this view, the diathesis–stress model suggests that the hypothal-
amus–pituitary–adrenal (HPA) axis may trigger a cascade of
events resulting in neural circuit dysfunction, including
alterations in DA signaling [146]. Epidemiological studies are
consistent with a key role of stress/cortisol in the onset of psy-
chosis. Higher levels of diurnal cortisol have been reported in
patients compared with controls or patients on antipsychotic
treatments for less than 2 weeks [147] and high baseline cortisol
levels appear to facilitate transition to psychotic level symptoms
in at-risk youths [148]. Mizrahi et al., investigating the DA re-
lease in response to a psychosocial stress challenge in psychosis-
related disorders, found that the largest stress-induced changes in
salivary cortisolwas present in the schizophrenia group, followed
by the clinical high-risk group, with an association between the
percent change in the cortisol response and the stress-induced
DA release in the associative striatum [149].
New data provide intriguing evidence of an association be-
tween migration [150], hearing impairment [151], childhood
abuse [152], low parental care [153], and elevation in striatal
dopamine synthesis. Acute administration of THC, the active
ingredient of cannabis, has been reported to increase dopamine
release [154]. However, paradoxically, chronic cannabis use
[155] and also difficult premature birth [156] are associated with
decreased striatal dopamine. Perhaps DA receptor sensitivity or
dysregulation in response to stress may be one pathway through
which the different exposures interact with genetic vulnerability
to confer a higher risk of schizophrenia [144].
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A compelling case is made for the role of glutamate/NMDA
receptors in schizophrenia, originally suggested as a mechanism
underlying the psychotogenic effects of PCP and ketamine [157].
There is now strong evidence in support of the hypothesis that
hypofunction of NMDA receptors contributes to the symptoms
of schizophrenia [158, 159]; some reports suggest that dopamine
dysregulation in schizophrenia may be secondary to glutamater-
gic dysfunction in some cases at least [160, 161]. Furthermore,
glutamatergic neurotransmission has been shown to mediate the
effects of both acute and chronic stress [162].
Just as amphetamine-induced psychosis gave rise to the do-
pamine hypothesis and ketamine-induced psychosis to the gluta-
mate hypotheses, so cannabis-induced psychosis has provoked
interest in the endocannabinoid system [163]. Certainly, the en-
dogenous cannabinoid system (eCB) is altered in schizophrenia.
The CB1 receptor densities and anandamide levels have been
reported abnormally in patients with schizophrenia [164, 165];
among other function, the eCB system appears to regulate the
HPA axis [166–168]. It has been suggested that a dysregulation
of this system (that could be induced for example by exogenous
cannabis) can interact with neurotransmitter systems in such a
way that an “endocannabinoid hypothesis” can be integrated into
the neurobiological hypotheses of schizophrenia [164].
Another possible molecular mechanism underlying psychosis
risk is neuroinflammation and abnormalities of the immune sys-
tem [169, 170•]. A recent meta-analysis examining peripheral
inflammatory markers shows that somemarkers such as interleu-
kin 6 (IL-6), tumor necrosis factor α (TNFα), soluble IL-2 re-
ceptor (sIL-2R), and IL-1 receptor antagonist (IL-1RA) increase
in acute episodes and tend to decrease after successful treatment
[171]. The effects of childhood trauma on inflammation have
beenwell-studied. Individuals exposed to childhood trauma have
significantly elevated baseline peripheral inflammatory markers
in adulthood [172, 173]. Another recently studied hypothesis
implicates the immune system. Autoimmune diseases are report-
ed to occur in 3.6% of patients with schizophrenia [174].
Mechanisms through which systemic immune activation affect
risk of psychopathology include the effects of inflammation on
concurrent brain function, the effects of early immune activation
on brain development, the sensitization of immune brain cells to
subsequent psychosocial stressors, and the cross-sensitization of
the HPA axis response to subsequent psychosocial stressors
[172]. It has been speculated that inflammation-mediated path-
ways may serve as a final common pathway for environmental
risk factors such as early childhood adversity, adolescent canna-
bis use, and social exclusion [170]. However, hard evidence
supporting this hypothesis remains elusive.
Conclusions
Epidemiological studies have consistently shown a pattern of
association between environmental risk factors and later onset
of psychosis, which is suggestive of a causal relationship.
However, there are a number of reasons why the association
between environmental risk factors and psychotic outcomes
may be overestimated or underestimated such as bias (where
incorrect estimates are due tomeasurements or sample selection),
chance, confounding (third explanation for the association), and
reverse causation (where psychosis increases risk of an environ-
mental exposure), which should be taken in consideration when
causality is inferred. Studying gene–environment interaction and
gene–environment correlation (rGE) (genetic effects on environ-
ment exposure) may clarify the position [175, 176].
Future research should also explore potential protective fac-
tors in groups who have a lower risk of psychotic disorders. A
new field of research includes big data and predictive models,
where traditional paper notes have been replaced with electronic
patient records. In line with this direction, there have been initial
successful applications of machine learning algorithms to diag-
nose psychosis [177]. As with diagnostic tools for cardiovascular
risk, schizophrenia will in the near future probably require a
combination of diagnostic approaches, including measures of
genetic risk, environmental risk factors, and imaging.
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